Aerovate Therapeutics, Inc. (AVTE) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Aerovate Therapeutics, Inc.

AVTE

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

78M

Biotechnology

Next Earning date - 12 May 2025

78M

Biotechnology

Next Earning date - 12 May 2025

2.68USD

-0.04 ( -1.47%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

Volume Buzz

319%

Earning Acce

Yes

Dist 52w H.

89%

Overview Chart

Quote Panel

Updated April 26, 2025

1W -3.25 % 1M 5.93 % 3M 4.28 % 1Y -86.96 %

Key Metrics

Market Cap
77.68M
Shares Outstanding
28.99M
Share in Float
21.13M
Dividende
0

Earning Date
12 May 2025
Price Target
2.68
Average Volume
259358
Beta
0.9462149

Range
1.25-25.285
Industry
Biotechnology
Website
https://aerovatetx.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

1.04x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-2.4

EPS

How AVTE compares to sector?

P/E Ratio

Fundamentals

Relative Strength

AVTE

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

AVTE

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$20M

NaN%

2026-Revenue

$0.79

-783%

2026-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Hold

Price Target

0.00(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Wells Fargo

downgrade

Previous: Overweight

2024-06-18

Now: Equal-Weight

Cowen & Co.

downgrade

Previous: Not converted

2024-06-17

Now: Hold

Guggenheim

downgrade

Previous: Not converted

2024-06-17

Now: Neutral

Jefferies

downgrade

Previous: Not converted

2024-06-17

Now: Hold

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-0.76
vs -0.49

Q3.23

N/A

-0.71
vs -0.56

Q4.23

N/A

-0.74
vs -0.61

Q1.24

N/A

-0.83
vs -0.67

Q2.24

N/A

-0.86
vs -0.76

Q3.24

N/A

-0.56
vs -0.71

Q4.24

N/A

-0.19
vs -0.74

Q1.25

+100%

NA
vs -0.83

Q2.25

N/A

-0.18
vs -0.86

Q3.25

N/A

-0.13
vs -0.56

Sales Growth

YoY

Current

Estimates

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

136K vs NA

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-100%

NA vs 136K

Q1.25

NA vs NA

Return on Equity

QoQ

Q2.23

-13%

-0.13
vs -0.14

Q3.23

-16%

-0.16
vs -0.13

Q4.23

-19%

-0.19
vs -0.16

Q1.24

-26%

-0.26
vs -0.19

Q2.24

-26%

-0.26
vs -0.26

Q3.24

-20%

-0.20
vs -0.26

Q4.24

-7%

-0.07
vs -0.20

Q1.25

-3%

-0.03
vs -0.07

Institutionnal Ownership

QoQ

Q1.23

65
vs 69

-6%

Q2.23

60
vs 65

-8%

Q3.23

58
vs 60

-3%

Q4.23

64
vs 58

10%

Q1.24

80
vs 64

25%

Q2.24

93
vs 80

16%

Q3.24

77
vs 93

-17%

Q4.24

83
vs 77

Earnings Growth

Latest News

prnewswire.com

8 hours ago

Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

prnewswire.com

8 hours ago

Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

businesswire.com

11 hours ago

AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE

businesswire.com

13 hours ago

AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders

prnewswire.com

16 hours ago

Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

globenewswire.com

18 hours ago

INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE

Company Description

2.68USD

N/A

0.00x

1.04x

0.0

0.0%

$-2.4

$20M

$0.79

Earnings Growth

Latest News

Company Description

2.68USD

$20M

$0.79

N/A

0.00x

1.04x

0.0

0.0%

$-2.4